Upgrade to SI Premium - Free Trial

Compass Pathways receives FDA rolling review for psychedelic depression drug

April 24, 2026 10:37 AM
Compass Pathways plc (NASDAQ: CMPS) announced the U.S. Food and Drug Administration granted the company a rolling New Drug Application ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

FDA

Next Articles